Feasibility of Using Cetuximab and Bevacizumab in a Patient with Colorectal Cancer and Terminal Renal Failure

Publisher： Karger

E-ISSN： 1423-0232|72|3-4|209-210

ISSN： 0030-2414

Source： Oncology, Vol.72, Iss.3-4, 2007-12, pp. : 209-210

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Effective Second-Line Treatment with Cetuximab and Bevacizumab in a Patient with Hepatic Metastases of Colorectal Cancer and Hyperbilirubinemia

By  

Oncology Research and Treatment, Vol. 30, Iss. 10, 2007-09 ,pp. : 509-512

Karger

Access to resources Recommend Favorite

Efficient and Safe Application of a FOLFIRI/Bevacizumab Combination to a Patient with Locally Advanced Rectal Cancer and Severe Chronic Renal Failure

By  

Oncology Research and Treatment, Vol. 30, Iss. 1-2, 2007-01 ,pp. : 65-65

Karger

Access to resources Recommend Favorite

Weekly Irinotecan in a Patient with Metastatic Colorectal Cancer on Hemodialysis due to Chronic Renal Failure

By  

Oncology Research and Treatment, Vol. 25, Iss. 1, 2002-03 ,pp. : 60-63

Karger

Access to resources Recommend Favorite

Complete Remission in a Colon Cancer Patient with a Large, Irresectable Liver Metastasis after XELOX/Cetuximab/Bevacizumab Treatment

By  

Oncology Research and Treatment, Vol. 31, Iss. 8-9, 2008-08 ,pp. : 464-467

Karger

Access to resources Recommend Favorite

Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC)

By Lawrence Donna   Maschio Michael   Leahy Kevin J.   Yunger Simon   Easaw Jacob C.   Weinstein Milton C.  

Journal of Medical Economics, Vol. 16, Iss. 12, 2013-12 ,pp. : 1387-1398

Informa Healthcare

Access to resources Recommend Favorite